Alaunos Therapeutics, Inc. Operating Expenses
Alaunos Therapeutics, Inc. (TCRT) reported Operating Expenses of $952.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-14
- Alaunos Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $952.00K, a 8.37% decline year-over-year.
- Alaunos Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $1.01M, a 7.50% decline year-over-year.
- Alaunos Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $910.00K, a 19.89% increase year-over-year.
- Alaunos Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $1.19M, a 3.22% increase year-over-year.
- Alaunos Therapeutics, Inc. operating expenses for fiscal 2025 was $4.23M, a 12.28% decline from fiscal 2024.
- Alaunos Therapeutics, Inc. operating expenses for fiscal 2024 was $4.82M, a 85.93% decline from fiscal 2023.
- Alaunos Therapeutics, Inc. operating expenses for fiscal 2023 was $34.27M, a 9.87% decline from fiscal 2022.
- Alaunos Therapeutics, Inc. operating expenses for fiscal 2022 was $38.03M, a 51.21% decline from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $952.00K 10-Q · filed 2026-08-14 | $1.96M 10-Q · filed 2026-08-14 | $2.87M derived: sum of 3 quarters · filed 2026-08-14 | $4.06M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.01M 10-Q · filed 2026-05-15 | $1.92M derived: sum of 2 quarters · filed 2026-05-15 | $3.11M derived: sum of 3 quarters · filed 2026-05-15 | $4.15M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $910.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.10M derived: sum of 2 quarters · filed 2026-03-31 | $3.14M derived: sum of 3 quarters · filed 2026-08-14 | $4.23M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.19M 10-Q · filed 2025-11-14 | $2.23M derived: sum of 2 quarters · filed 2026-08-14 | $3.32M 10-Q · filed 2025-11-14 | $4.08M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $1.04M 10-Q · filed 2026-08-14 | $2.13M 10-Q · filed 2026-08-14 | $2.89M derived: sum of 3 quarters · filed 2026-08-14 | $4.04M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $1.09M 10-Q · filed 2026-05-15 | $1.85M derived: sum of 2 quarters · filed 2026-05-15 | $3.00M derived: sum of 3 quarters · filed 2026-05-15 | $4.17M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $759.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.91M derived: sum of 2 quarters · filed 2026-03-31 | $3.08M derived: sum of 3 quarters · filed 2026-03-31 | $4.82M 10-K · filed 2026-03-31 |
| 2024-09-30 | $1.15M 10-Q · filed 2025-11-14 | $2.32M derived: sum of 2 quarters · filed 2025-11-14 | $4.06M 10-Q · filed 2025-11-14 | $12.01M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $1.17M 10-Q · filed 2025-08-14 | $2.91M 10-Q · filed 2025-08-14 | $10.86M derived: sum of 3 quarters · filed 2025-08-14 | $19.53M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.74M 10-Q · filed 2025-05-15 | $9.69M derived: sum of 2 quarters · filed 2025-05-15 | $18.36M derived: sum of 3 quarters · filed 2025-05-15 | $26.34M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $7.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $16.61M derived: sum of 2 quarters · filed 2025-03-31 | $24.60M derived: sum of 3 quarters · filed 2025-03-31 | $34.27M 10-K · filed 2025-03-31 |
| 2023-09-30 | $8.66M 10-Q · filed 2024-11-14 | $16.65M derived: sum of 2 quarters · filed 2024-11-14 | $26.32M 10-Q · filed 2024-11-14 | $34.85M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $7.99M 10-Q · filed 2024-08-14 | $17.66M 10-Q · filed 2024-08-14 | $26.19M derived: sum of 3 quarters · filed 2024-08-14 | $37.37M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $9.67M 10-Q · filed 2024-05-15 | $18.20M derived: sum of 2 quarters · filed 2024-05-15 | $29.38M derived: sum of 3 quarters · filed 2024-05-15 | $38.61M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $8.53M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $19.71M derived: sum of 2 quarters · filed 2024-04-01 | $28.94M derived: sum of 3 quarters · filed 2024-04-01 | $38.03M 10-K · filed 2024-04-01 |
| 2022-09-30 | $11.18M 10-Q · filed 2023-11-14 | $20.41M derived: sum of 2 quarters · filed 2023-11-14 | $29.50M 10-Q · filed 2023-11-14 | $40.54M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $9.23M 10-Q · filed 2023-08-14 | $18.32M 10-Q · filed 2023-08-14 | $29.37M derived: sum of 3 quarters · filed 2023-08-14 | $52.06M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $9.09M 10-Q · filed 2023-05-10 | $20.14M derived: sum of 2 quarters · filed 2023-05-10 | $42.83M derived: sum of 3 quarters · filed 2023-05-10 | $65.47M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $11.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $33.74M derived: sum of 2 quarters · filed 2023-03-07 | $56.38M derived: sum of 3 quarters · filed 2023-03-07 | $77.95M 10-K · filed 2023-03-07 |
| 2021-09-30 | $22.69M 10-Q · filed 2022-11-14 | $45.33M derived: sum of 2 quarters · filed 2022-11-14 | $66.90M 10-Q · filed 2022-11-14 | $89.67M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $22.64M 10-Q · filed 2022-08-15 | $44.20M 10-Q · filed 2022-08-15 | $66.98M derived: sum of 3 quarters · filed 2022-08-15 | $87.30M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $21.56M 10-Q · filed 2022-05-16 | $44.34M derived: sum of 2 quarters · filed 2022-05-16 | $64.66M derived: sum of 3 quarters · filed 2022-05-16 | $83.26M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $22.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $43.09M derived: sum of 2 quarters · filed 2022-03-30 | $61.70M derived: sum of 3 quarters · filed 2022-03-30 | $80.36M 10-K · filed 2022-03-30 |
| 2020-09-30 | $20.32M 10-Q · filed 2021-11-08 | $38.93M derived: sum of 2 quarters · filed 2021-11-08 | $57.59M 10-Q · filed 2021-11-08 | $73.62M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $18.61M 10-Q · filed 2021-08-13 | $37.27M 10-Q · filed 2021-08-13 | $53.30M derived: sum of 3 quarters · filed 2021-08-13 | $66.75M derived: sum of 4 quarters · filed 2021-08-13 |
| 2020-03-31 | $18.66M 10-Q · filed 2021-05-06 | $34.70M derived: sum of 2 quarters · filed 2021-05-06 | $48.14M derived: sum of 3 quarters · filed 2021-05-06 | $62.90M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $16.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $29.48M derived: sum of 2 quarters · filed 2021-03-01 | $44.24M derived: sum of 3 quarters · filed 2021-03-01 | $57.86M 10-K · filed 2021-03-01 |
| 2019-09-30 | $13.45M 10-Q · filed 2020-11-05 | $28.20M derived: sum of 2 quarters · filed 2020-11-05 | $41.82M 10-Q · filed 2020-11-05 | $54.58M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $14.75M 10-Q · filed 2020-08-06 | $28.37M 10-Q · filed 2020-08-06 | $41.14M derived: sum of 3 quarters · filed 2021-03-01 | $53.71M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $13.62M 10-Q · filed 2020-05-07 | $26.38M derived: sum of 2 quarters · filed 2021-03-01 | $38.95M derived: sum of 3 quarters · filed 2021-03-01 | $51.33M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $12.76M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $25.33M derived: sum of 2 quarters · filed 2021-03-01 | $37.71M derived: sum of 3 quarters · filed 2021-03-01 | $54.05M 10-K · filed 2021-03-01 |
| 2018-09-30 | $12.57M 10-Q · filed 2019-11-07 | $24.95M derived: sum of 2 quarters · filed 2019-11-07 | $41.29M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $12.38M 10-Q · filed 2019-08-08 | $28.72M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $16.34M 10-Q · filed 2019-05-08 | |||
| 2017-12-31 | $59.88M 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |